Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences
Jati, Yohanes Surya
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Earth & Planetary Sciences

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Cell Cycle Target Protein Induced by Galangin Treatment in Luminal Cells Confirmed by Bioinformatics Analysis Sekarini, Diyah Novi; Jati, Yohanes Surya; Zulkepli, Nur Ayunie; Putri, Dyaningtyas Dewi Pamungkas
HAYATI Journal of Biosciences Vol. 32 No. 4 (2025): July 2025
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.32.4.969-979

Abstract

Galangin has activity modulating cell cycle arrest on luminal cancer cells and has high selectivity and low cytotoxicity for normal cells. This research intends to know galangin's prospective targets for promoting cell cycle arrest in luminal breast cancer via experimental in vitro, network pharmacology, and bioinformatics validation. In this research, MCF-7, a luminal model cell, was treated with galangin dose-dependent. Consequently, galangin exhibited a cytotoxic impact, with IC50 values of 117.86 μM. After that, SwissTargetPrediction, UALCAN, ShinyGO, and OncoLnc were used for bioinformatics validations, and Cytoscape software and the STRING website were used for computational analysis. Eight overlapping galangin target genes against luminal breast cancer were found. According to the analysis of the protein-protein interaction (PPI) network, eight hub genes-including CDK1, PLK1, TOP2A, ESR1, AURKB, NEK2, MMP9, and CA12-had the highest degree of freedom. Cell cycle regulation has been discovered to be tightly associated with overexpression of CDK1, PLK1, AURKB, and NEK2. By influencing the cell cycle, galangin inhibits the growth of luminal breast cancer, as determined by GO and KEGG enrichment analyses. In conclusion, by triggering cell cycle arrest, galangin may be used as a prospective chemotherapeutic treatment.
Co-Authors Dyaningtyas Dewi Putri Pamungkas Sekarini, Diyah Novi Zulkepli, Nur Ayunie